We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Aduhelm Could Account for 1 Percent of U.S. Drug Spending by 2025, Says Research Group
Aduhelm Could Account for 1 Percent of U.S. Drug Spending by 2025, Says Research Group
Biogen’s controversial Alzheimer’s drug Aduhelm (aducanumab) could account for more than 1 percent of all U.S. prescription drug spending by 2025, a health research group predicted this week.